Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome
Ver/ Abrir
Identificadores
URI: http://hdl.handle.net/10902/21322DOI: 10.3390/ijms21186906
ISSN: 1661-6596
ISSN: 1422-0067
Registro completo
Mostrar el registro completo DCFecha
2020Derechos
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.
Publicado en
Int J Mol Sci
. 2020 Sep 20;21(18):6906
Editorial
MDPI
Enlace a la publicación
Palabras clave
Alzheimer’s Disease
Down Syndrome
Neurodegeneration
Signalling Pathways
Resumen/Abstract
Down syndrome (DS), the most common cause of intellectual disability of genetic origin, is characterized by alterations in central nervous system morphology and function that appear from early prenatal stages. However, by the fourth decade of life, all individuals with DS develop neuropathology identical to that found in sporadic Alzheimer's disease (AD), including the development of amyloid plaques and neurofibrillary tangles due to hyperphosphorylation of tau protein, loss of neurons and synapses, reduced neurogenesis, enhanced oxidative stress, and mitochondrial dysfunction and neuroinflammation. It has been proposed that DS could be a useful model for studying the etiopathology of AD and to search for therapeutic targets. There is increasing evidence that the neuropathological events associated with AD are interrelated and that many of them not only are implicated in the onset of this pathology but are also a consequence of other alterations. Thus, a feedback mechanism exists between them. In this review, we summarize the signalling pathways implicated in each of the main neuropathological aspects of AD in individuals with and without DS as well as the interrelation of these pathways.
Colecciones a las que pertenece
- D16 Artículos [196]